Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Du

Patients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high unmet needsLate-breaking data to be presented during the 2023 American Society of Clinical Oncology...

Related Keywords

United States , Japan , China , American , Davidp Carbone , , Thoracic Oncology Center , American Society Of Clinical Oncology , Ohio State University Comprehensive Cancer Center , Solove Research Institute , Bristol Myers Squibb , Company Opdivo , European Union , Drug Administration , American Society Of Clinical Oncology Annual Meeting , Clinical Oncology Annual , Hazard Ratio , Confidence Interval , Clinical Oncology , Annual Meeting , James Cancer Hospital , Solove Research , Myers Squibb , Better Future , Fatal Immune Mediated Adverse , Full Prescribing Information ,